Juvenile arthritis

Bielak M et al. Pediatr Rheumatol 2018; 16: 22. doi: 10.1186/s12969-018-0236-y

Constantin T et al. Ann Rheum Dis 2018; Advance online publication. doi: 10.1136/annrheumdis-2018-213131

Rubbert-Roth A et al. Rheumatol Ther 2018; Advance online publication. doi: 10.1007/s40744-018-0102-x

Ramanan AV et al. BMC Rheumatol 2018; 2: 4. doi: 10.1186/s41927-018-0010-2

Wampler TL, Niewold TB. Nat Rev Rheumatol 2018; 14: 214–228. doi: 10.1038/nrrheum.2018.31

Barturen G et al. Nat Rev Rheumatol 2018; 14: 75–93. doi: 10.1038/nrrheum.2017.220

This review article by Asproudis et al. provides an overview of the treatment of chronic uveitis, a common extra-articular manifestation of juvenile idiopathic arthritis.

Asproudis I et al. Adv Ther 2017;34:2558–2565. doi:10.1007/s12325-017-0635-3

The authors review the published data about methotrexate-induced nausea in the treatment of juvenile idiopathic arthritis, as well as possible management approaches including the use of newer antinausea medications.

Falvey S, Shipman L, Ilowite N, Beukelman T. Pediatr Rheumatol 2017;15:52. doi:10.1186/s12969-017-0180-2

This study finds that ultrasound-guided tendon sheath injections, a frequently performed procedure in patients with juvenile idiopathic arthritis, are a safe intervention with a high technical success rate.

Peters SE, Laxer RM, Connolly BL, Parra DA. Pediatr Rheumatol 2017;15:22. doi:10.1186/s12969-017-0155-3

The author discusses sexual function and fertility in rheumatic disease, suggesting that successful management should include regular family planning, effective treatment, sexual counseling, and infertility treatment.

Nat Rev Rheumatol 2017;13:485–493. doi:10.1038/nrrheum.2017.102

In this review, Vanoni et al. summarize the currently available biologics used in juvenile idiopathic arthritis, highlighting how these have improved outcomes and the quality of life of patients.

Vanoni F, Minoia F, Malattia C. Eur J Pediatr 2017;176:1147–1153. doi:10.1007/s00431-017-2960-6

Coda et al. describe how by embracing and adapting new and highly-accessible interactive technologies, clinical management and research of juvenile idiopathic arthritis may be greatly advanced.

Coda A, Sculley D, Santos D et al. Pediatr Rheumatol 2017;15:40. doi:10.1186/s12969-017-0168-y

This study used claims data to compare rates of hospitalized infection among children with juvenile idiopathic arthritis initiating treatment with a biologic agent versus initiating methotrexate treatment.

Beukelmam T, Xie F, Baddley JW, et al. Arthritis Res Ther 2016;18:210. doi:10.1186/s13075-016-1109-8

This review focuses on the risk of serious infections in patients with rheumatoid arthritis receiving treatment with a biologic, with an emphasis on helping clinicians and patients make treatment decisions.

Singh JA. Curr Rheumatol Rep 2016;18:61. doi:10.1007/s11926-016-0609-5

An expert review of the developments from the past 15 years and future direction of biologic therapy for the treatment of juvenile idiopathic arthritis.

Sterba Y & Ilowite N. Curr Rheumatol Rep 2016;18:45. doi:10.1007/s11926-016-0593-9

A population-based cohort evaluated medication and intra-articular injection use for patients with juvenile idiopathic arthritis to inform clinical practice and further research.

Zamora-Legoff JA et al. Clin Rheumatol 2016;35:1493–1499. doi:10.1007/s10067-016-3190-4

This chapter illustrates both the non-pharmacologic and pharmacologic therapeutic approaches for managing patients with juvenile idiopathic arthritis.

Handbook of Juvenile Idiopathic Arthritis. Springer International Publishing, 2016. doi:10.1007/978-3-319-08102-1_7

This review explores the application of ‘treat-to-target’ and tight control strategies for juvenile idiopathic arthritis, and the likely development of future clinical guidelines or treatment protocols.

Nat Rev Rheumatol 2015;11:290–300. doi:10.1038/nrrheum.2014.212